Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Zogenix Inc (ZGNX)

Zogenix Inc (ZGNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,375,665
  • Shares Outstanding, K 55,448
  • Annual Sales, $ 3,650 K
  • Annual Income, $ -419,500 K
  • 60-Month Beta 1.63
  • Price/Sales 376.34
  • Price/Cash Flow N/A
  • Price/Book 3.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -1.00
  • Number of Estimates 5
  • High Estimate -0.95
  • Low Estimate -1.06
  • Prior Year -0.95
  • Growth Rate Est. (year over year) -5.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.09 +7.97%
on 08/06/20
29.89 -16.59%
on 07/20/20
-2.47 (-9.01%)
since 07/14/20
3-Month
23.09 +7.97%
on 08/06/20
32.42 -23.10%
on 06/26/20
-1.37 (-5.21%)
since 05/14/20
52-Week
16.65 +49.73%
on 03/18/20
57.22 -56.43%
on 01/17/20
-23.40 (-48.42%)
since 08/14/19

Most Recent Stories

More News
Shares of ZGNX Down 3.4% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Zogenix Inc (NASDAQ:ZGNX) on June 29th, 2020 at $25.69. In approximately 2 months, Zogenix Inc has returned 3.43% as of today's recent price of $24.81.

ZGNX : 24.93 (+0.48%)
Zogenix (ZGNX) Reports Q2 Loss, Misses Revenue Estimates

Zogenix (ZGNX) delivered earnings and revenue surprises of 5.88% and -6.18%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

ZGNX : 24.93 (+0.48%)
Zogenix: 2Q Earnings Snapshot

EMERYVILLE, Calif. (AP) _ Zogenix Inc. (ZGNX) on Wednesday reported a loss of $53.3 million in its second quarter.

ZGNX : 24.93 (+0.48%)
Zogenix to Release Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 5

Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and six months ended June 30, 2020,...

ZGNX : 24.93 (+0.48%)
Earnings Preview: Zogenix (ZGNX) Q2 Earnings Expected to Decline

Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ZGNX : 24.93 (+0.48%)
Zogenix Gets FDA Nod for Dravet Syndrome Seizure Treatment

Zogenix (ZGNX) gets FDA nod for Fintepla oral solution, CIV for the treatment of seizures associated with Dravet Syndrome in patients 2 years of age or older.

ZGNX : 24.93 (+0.48%)
MEIP : 2.80 (-2.78%)
GWPH : 106.43 (-1.89%)
AMRX : 4.25 (-0.47%)
FDA Approves FINTEPLA® (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome

, /PRNewswire/ -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved FINTEPLA...

ZGNX : 24.93 (+0.48%)
Watch for Zogenix Inc to Potentially Pullback After Gaining 3.00% Yesterday

Zogenix Inc (NASDAQ:ZGNX) traded in a range yesterday that spanned from a low of $28.73 to a high of $29.55. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $29.17...

ZGNX : 24.93 (+0.48%)
Are Options Traders Betting on a Big Move in Zogenix (ZGNX) Stock?

Investors need to pay close attention to Zogenix (ZGNX) stock based on the movements in the options market lately.

ZGNX : 24.93 (+0.48%)
Zogenix Introduces New Resources for Dravet Syndrome Siblings

Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced the introduction in the U.S. of a new suite of materials to better support and celebrate...

ZGNX : 24.93 (+0.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ZGNX with:

Business Summary

Zogenix is a specialty biopharmaceutical company focused on developing therapies for patients with rare central nervous system conditions that have limited or no treatment options. The company is currently pursuing two therapies targeting the Dravet Syndrome and the Lennox-Gastaut Syndrome.

See More

Key Turning Points

2nd Resistance Point 25.51
1st Resistance Point 25.22
Last Price 24.93
1st Support Level 24.41
2nd Support Level 23.89

See More

52-Week High 57.22
Fibonacci 61.8% 41.72
Fibonacci 50% 36.94
Fibonacci 38.2% 32.15
Last Price 24.93
52-Week Low 16.65

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar